Explore 3 Stock Ideas & Industry Insights Download Free Report
The answer is precise and deliberately narrow. Voydeya is approved in the US, the EU and Great Britain only as an add-on therapy to the C5 inhibitors ravulizumab or eculizumab in adults with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia — described …
The strategic logic is complementarity. Voydeya is designed to address residual, clinically significant extravascular haemolysis (EVH) in patients already on a C5 backbone — a defined subgroup rather than the whole PNH population. It therefore deepens AstraZeneca's complement franchise around Ultomiris and Soliris instead …
Rather than relying on a single blockbuster indication, AstraZeneca has widened Imfinzi across lung, gastrointestinal, genitourinary and gynaecological cancers, with approvals in the UK, EU and US. Each new indication, and each move from advanced disease into neoadjuvant or adjuvant treatment, is intended to …
1.Imfinzi (durvalumab) is AstraZeneca's wholly owned anti-PD-L1 immune checkpoint inhibitor, approved across the UK, EU and US in a broadening set of cancers.
LSE:AZN - AstraZeneca PLC edged lower by approximately1.28%during today's trading session as investors booked profits following recent resilience in defensive healthcare stocks.
LSE:HLMA - Halma plc came under modest selling pressure today, declining approximately1.98%as investors rotated away from premium valuation defensive growth stocks.
RUA Life Sciences Plc (LSE: RUA)RUA Life Sciences plc develops and manufactures biostable polymer materials and components used in the design of next-generation implantable medical devices, including heart valves and vascular grafts.
Avacta Group PLC (AVCT)Avacta Group PLC is a life sciences company developing Affimer-based therapeutics and diagnostic technologies, including applications in oncology.
IXICO Plc (IXI)IXICO Plc provides imaging-based biomarker and data analytics services that support clinical trials for neurodegenerative diseases such as Alzheimer's and Huntington's disease.
ImmuPharma plc: Key Reasons Driving Growth, Growth Catalysts, Risks, Valuation and Technical Outlook
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…